knowledge -WSS

knowledge

author：explore 2025-09-30 19:25:08 - browse：23

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Why a market frenzy over new weight loss drugs defies logic

WSS

STAT Readout: Friday, Oct. 20 biotech updates

Smaller biotechs seek to piggyback on weight loss drug boom

House looks to weaken Medicare negotiation

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Clinical trials giant ICON acquires HumanFirst

knowledge

knowledge

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Obesity now affects over 1 billion people worldwide, study finds

Affirmative action in medical school literally saved lives

FogPharma raises $145 million in rare Series E round

Peter Hotez and the public health issue of online harassment

Roche drug slashes death risk in early

In Memoriam: Notable people who died in 2023

How AI can help patients find reliable information about doctors

Trump demands the U.S. pay no more for drugs than other countries … again

A Q&A with Aletha Maybank, AMA’s chief health equity officer

knowledge

ADCs take center stage as promising cancer treatments

ALS groups 'won't be played again' by the FDA, drug sponsors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Results on Novartis prostate cancer therapy could expand its use

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

leisure time

focus

explore